1. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: Old questions and new insights. Science. 2011;332:1519–1523. doi: 10.1126/science.1204265. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Wei J.L., Leung J.C.-F., Loong T.C.-W., Wong G.L.-H., Yeung D.K.-W., Chan R.S.-M., Chan H.L., Chim A.M., Woo J., Chu W.C., et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: A population study using proton-magnetic resonance spectroscopy. Am. J. Gastroenterol. 2015;110:1306–1314. doi: 10.1038/ajg.2015.235. [PubMed] [CrossRef] [Google Scholar]
3. Ishimoto T., Lanaspa M.A., Rivard C.J., Roncal-Jimenez C.A., Orlicky D.J., Cicerchi C., McMahan R.H., Abdelmalek M.F., Rosen H.R., Jackman M.R., et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology. 2013;58:1632–1643. doi: 10.1002/hep.26594. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Lim J.S., Mietus-Snyder M., Valente A., Schwarz J.-M., Lustig R.H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol. 2010;7:251–264. doi: 10.1038/nrgastro.2010.41. [PubMed] [CrossRef] [Google Scholar]
5. Basaranoglu M., Basaranoglu G., Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: Fructose as a weapon of mass destruction. Hepatobiliary Surg. Nutr. 2015;4:109–116. [PMC free article] [PubMed] [Google Scholar]
6. Bray G.A., Popkin B.M. Dietary sugar and body weight: Have we reached a crisis in the epidemic of obesity and diabetes?: Health be damned! Pour on the sugar. Diabetes Care. 2014;37:950–956. doi: 10.2337/dc13-2085. [PubMed] [CrossRef] [Google Scholar]
7. Abdelmalek M.F., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R.J., Diehl A.M. Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971. doi: 10.1002/hep.23535. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Alwahsh S.M., Xu M., Seyhan H.A., Ahmad S., Mihm S., Ramadori G., Schultze F.C. Diet high in fructose leads to an overexpression of lipocalin-2 in rat fatty liver. World J. Gastroenterol. 2014;20:1807–1821. doi: 10.3748/wjg.v20.i7.1807. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Sellmann C., Priebs J., Landmann M., Degen C., Engstler A.J., Jin C.J., Gärttner S., Spruss A., Huber O., Bergheim I. Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. J. Nutr. Biochem. 2015;26:1183–1192. doi: 10.1016/j.jnutbio.2015.05.011. [PubMed] [CrossRef] [Google Scholar]
10. Yki-Järvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients. 2015;7:9127–9138. doi: 10.3390/nu7115454. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Orci L.A., Gariani K., Oldani G., Delaune V., Morel P., Toso C. Exercise-based interventions for nonalcoholic fatty liver disease: A meta-analysis and meta-regression. Clin. Gastroenterol. Hepatol. 2016;14:1398–1411. doi: 10.1016/j.cgh.2016.04.036. [PubMed] [CrossRef] [Google Scholar]
12. Softic S., Cohen D.E., Kahn C.R. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig. Dis. Sci. 2016;61:1282–1293. doi: 10.1007/s10620-016-4054-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Schwarz J.-M., Noworolski S.M., Wen M.J., Dyachenko A., Prior J.L., Weinberg M.E., Herraiz L.A., Tai V.W., Bergeron N., Bersot T.P., et al. Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. J. Clin. Endocrinol. Metab. 2015;100:2434–2442. doi: 10.1210/jc.2014-3678. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
14. Sobrecases H., Lê K.-A., Bortolotti M., Schneiter P., Ith M., Kreis R., Boesch C., Tappy L. Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. Diabetes Metab. 2010;36:244–246. doi: 10.1016/j.diabet.2010.03.003. [PubMed] [CrossRef] [Google Scholar]
15. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M., Johnson R.J., Abdelmalek M.F. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 2008;48:993–999. doi: 10.1016/j.jhep.2008.02.011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
16. Tappy L., Lê K.-A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 2010;90:23–46. doi: 10.1152/physrev.00019.2009. [PubMed] [CrossRef] [Google Scholar]
17. Herman M.A., Samuel V.T. The sweet path to metabolic demise: Fructose and lipid synthesis. Trends Endocrinol. Metab. 2016;27:719–730. doi: 10.1016/j.tem.2016.06.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Jegatheesan P., Beutheu S., Ventura G., Nubret E., Sarfati G., Bergheim I., De Bandt J.P. Citrulline and nonessential amino acids prevent fructose-induced nonalcoholic fatty liver disease in rats. J. Nutr. 2015;145:2273–2279. doi: 10.3945/jn.115.218982. [PubMed] [CrossRef] [Google Scholar]
19. Jegatheesan P., Beutheu S., Freese K., Waligora-Dupriet A.-J., Nubret E., Butel M.-J., Bergheim I., De Bandt J.P. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats. Br. J. Nutr. 2016;116:191–203. doi: 10.1017/S0007114516001793. [PubMed] [CrossRef] [Google Scholar]
20. Mastrocola R., Nigro D., Cento A.S., Chiazza F., Collino M., Aragno M. High-fructose intake as risk factor for neurodegeneration: Key role for carboxy methyllysine accumulation in mice hippocampal neurons. Neurobiol. Dis. 2016;89:65–75. doi: 10.1016/j.nbd.2016.02.005. [PubMed] [CrossRef] [Google Scholar]
21. Theytaz F., de Giorgi S., Hodson L., Stefanoni N., Rey V., Schneiter P., Giusti V., Tappy L. Metabolic fate of fructose ingested with and without glucose in a mixed meal. Nutrients. 2014;6:2632–2649. doi: 10.3390/nu6072632. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Lanaspa M.A., Sanchez-Lozada L.G., Choi Y.-J., Cicerchi C., Kanbay M., Roncal-Jimenez C.A., Ishimoto T., Li N., Marek G., Duranay M., et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: Potential role in fructose-dependent and -independent fatty liver. J. Biol. Chem. 2012;287:40732–40744. doi: 10.1074/jbc.M112.399899. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Madlala H.P., Maarman G.J., Ojuka E. Uric acid and transforming growth factor in fructose-induced production of reactive oxygen species in skeletal muscle. Nutr. Rev. 2016;74:259–266. doi: 10.1093/nutrit/nuv111. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. Wei Y., Wang D., Moran G., Estrada A., Pagliassotti M.J. Fructose-induced stress signaling in the liver involves methylglyoxal. Nutr. Metab. (Lond.) 2013;10:32. doi: 10.1186/1743-7075-10-32. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
25. Allaman I., Bélanger M., Magistretti P.J. Methylglyoxal, the dark side of glycolysis. Front. Neurosci. 2015;9:23. doi: 10.3389/fnins.2015.00023. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Lê K.-A., Faeh D., Stettler R., Debard C., Loizon E., Vidal H., Boesch C., Ravussin E., Tappy L. Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008;34:82–85. doi: 10.1016/j.diabet.2007.08.004. [PubMed] [CrossRef] [Google Scholar]
27. Nigro D., Menotti F., Cento A.S., Serpe L., Chiazza F., dal Bello F., Romaniello F., Medana C., Collino M., Aragno M., et al. Chronic administration of saturated fats and fructose differently affect SREBP activity resulting in different modulation of Nrf2 and Nlrp3 inflammasome pathways in mice liver. J. Nutr. Biochem. 2017;42:160–171. doi: 10.1016/j.jnutbio.2017.01.010. [PubMed] [CrossRef] [Google Scholar]
28. Pérez-Carreras M., Del Hoyo P., Martín M.A., Rubio J.C., Martín A., Castellano G., Colina F., Arenas J., Solis-Herruzo J.A. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38:999–1007. doi: 10.1002/hep.1840380426. [PubMed] [CrossRef] [Google Scholar]
29. Satapati S., Sunny N.E., Kucejova B., Fu X., He ., Méndez-Lucas A., Shelton J.M., Perales J.C., Browning J.D., Burgess S.C. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J. Lipid Res. 2012;53:1080–1092. doi: 10.1194/jlr.M023382. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
30. Fu S., Watkins S.M., Hotamisligil G.S. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab. 2012;15:623–634. doi: 10.1016/j.cmet.2012.03.007. [PubMed] [CrossRef] [Google Scholar]
31. Foufelle F., Ferré P. Unfolded protein response: Its role in physiology and physiopathology. Med. Sci. (Paris) 2007;23:291–296. doi: 10.1051/medsci/2007233291. [PubMed] [CrossRef] [Google Scholar]
32. Zhang X.-Q., Xu C.-F., Yu C.-H., Chen W.-X., Li Y.-M. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J. Gastroenterol. 2014;20:1768–1776. doi: 10.3748/wjg.v20.i7.1768. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
34. Dekker M.J., Su Q., Baker C., Rutledge A.C., Adeli K. Fructose: A highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 2010;299:E685–E694. doi: 10.1152/ajpendo.00283.2010. [PubMed] [CrossRef] [Google Scholar]
35. Zámbó V., Simon-Szabó L., Szelényi P., Kereszturi E., Bánhegyi G., Csala M. Lipotoxicity in the liver. World J. Hepatol. 2013;5:550–557. [PMC free article] [PubMed] [Google Scholar]
36. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. J. Hepatol. 2009;51:212–223. doi: 10.1016/j.jhep.2009.03.008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
38. Brunt E.M., Tiniakos D.G. Pathological features of NASH. Front. Biosci. 2005;10:1475–1484. [PubMed] [Google Scholar]
39. Ilan Y. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis. World J. Gastroenterol. 2012;18:2609–2618. doi: 10.3748/wjg.v18.i21.2609. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
40. Stefan N., Häring H.-U. The role of hepatokines in metabolism. Nat. Rev. Endocrinol. 2013;9:144–152. doi: 10.1038/nrendo.2012.258. [PubMed] [CrossRef] [Google Scholar]
41. Iroz A., Couty J.-P., Postic C. Hepatokines: Unlocking the multi-organ network in metabolic diseases. Diabetologia. 2015;58:1699–1703. doi: 10.1007/s00125-015-3634-4. [PubMed] [CrossRef] [Google Scholar]
43. Ma H.-D., Wang Y.-H., Chang C., Gershwin M.E., Lian Z.-X. The intestinal microbiota and microenvironment in liver. Autoimmun. Rev. 2015;14:183–191. doi: 10.1016/j.autrev.2014.10.013. [PubMed] [CrossRef] [Google Scholar]
44. De Bandt J.-P., Waligora-Dupriet A.-J., Butel M.-J. Intestinal microbiota in inflammation and insulin resistance: Relevance to humans. Curr. Opin. Clin. Nutr. Metab. Care. 2011;14:334–340. doi: 10.1097/MCO.0b013e328347924a. [PubMed] [CrossRef] [Google Scholar]
46. Jegatheesan P., Beutheu S., Ventura G., Sarfati G., Nubret E., Kapel N., Waligora-Dupriet A.J., Bergheim I., Cynober L., De-Bandt J.P. Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease. Clin. Nutr. 2016;35:175–182. doi: 10.1016/j.clnu.2015.01.021. [PubMed] [CrossRef] [Google Scholar]
47. Ritze Y., Bárdos G., Claus A., Ehrmann V., Bergheim I., Schwiertz A., Bischoff S.C. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS ONE. 2014;9:e80169. doi: 10.1371/journal.pone.0080169. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
48. Giannelli V., di Gregorio V., Iebba V., Giusto M., Schippa S., Merli M., Thalheimer U. Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis. World J. Gastroenterol. 2014;20:16795–16810. doi: 10.3748/wjg.v20.i45.16795. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
49. Compare D., Coccoli P., Rocco A., Nardone O.M., de Maria S., Cartenì M., Nardone G. Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2012;22:471–476. doi: 10.1016/j.numecd.2012.02.007. [PubMed] [CrossRef] [Google Scholar]
50. Bilzer M., Roggel F., Gerbes A.L. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006;26:1175–1186. doi: 10.1111/j.1478-3231.2006.01342.x. [PubMed] [CrossRef] [Google Scholar]
51. Johnson A.R., Milner J.J., Makowski L. The inflammation highway: Metabolism accelerates inflammatory traffic in obesity. Immunol. Rev. 2012;249:218–238. doi: 10.1111/j.1600-065X.2012.01151.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
52. Campos V.C., Tappy L. Physiological handling of dietary fructose-containing sugars: Implications for health. Int. J. Obes. (Lond.) 2016;40:S6–S11. doi: 10.1038/ijo.2016.8. [PubMed] [CrossRef] [Google Scholar]
53. Stanhope K.L., Schwarz J.M., Keim N.L., Griffen S.C., Bremer A.A., Graham J.L., Hatcher B., Cox C.L., Dyachenko A., Zhang W., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J. Clin. Investig. 2009;119:1322–1334. doi: 10.1172/JCI37385. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Alwahsh S.M., Dwyer B.J., Forbes S., van Thiel D.H., Lewis P.J.S., Ramadori G. Insulin Production and Resistance in Different Models of Diet-Induced Obesity and Metabolic Syndrome. Int. J. Mol. Sci. 2017;18:285. doi: 10.3390/ijms18020285. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
55. Vrána A., Fábry P., Kazdová L. Effect of dietary fructose on fatty acid synthesis in adipose tissue and on triglyceride concentration in blood in the rat. Nutr. Metab. 1973;15:305–313. doi: 10.1159/000175454. [PubMed] [CrossRef] [Google Scholar]
56. Masterjohn C., Park Y., Lee J., Noh S.K., Koo S.I., Bruno R.S. Dietary fructose feeding increases adipose methylglyoxal accumulation in rats in association with low expression and activity of glyoxalase-2. Nutrients. 2013;5:3311–3328. doi: 10.3390/nu5083311. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
57. Jia X., Wu L. Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Mol. Cell. Biochem. 2007;306:133–139. doi: 10.1007/s11010-007-9563-x. [PubMed] [CrossRef] [Google Scholar]
58. Du L., Heaney A.P. Regulation of adipose differentiation by fructose and GluT5. Mol. Endocrinol. 2012;26:1773–1782. doi: 10.1210/me.2012-1122. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
59. Rippe J.M., Angelopoulos T.J. Sucrose, high-fructose corn syrup, and fructose, their metabolism and potential health effects: What do we really know? Adv. Nutr. 2013;4:236–245. doi: 10.3945/an.112.002824. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
60. Fernández-Novell J.M., Ramió-Lluch L., Orozco A., Gómez-Foix A.M., Guinovart J.J., Rodríguez-Gil J.E. Glucose and fructose have sugar-specific effects in both liver and skeletal muscle in vivo: A role for liver fructokinase. PLoS ONE. 2014;9:e109726. doi: 10.1371/journal.pone.0109726. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
61. Deldicque L., Cani P.D., Philp A., Raymackers J.-M., Meakin P.J., Ashford M.L.J., Delzenne N.M., Francaux M., Baar K. The unfolded protein response is activated in skeletal muscle by high-fat feeding: Potential role in the downregulation of protein synthesis. Am. J. Physiol. Endocrinol. Metab. 2010;299:E695–E705. doi: 10.1152/ajpendo.00038.2010. [PubMed] [CrossRef] [Google Scholar]
62. Rieu I., Magne H., Savary-Auzeloux I., Averous J., Bos C., Peyron M.A., Combaret L., Dardevet D. Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats. J. Physiol. (Lond.) 2009;587:5483–5492. doi: 10.1113/jphysiol.2009.178319. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. Jegatheesan P., de Bandt J.-P. Hepatic steatosis: A role for citrulline. Curr. Opin. Clin. Nutr. Metab. Care. 2016;19:360–365. doi: 10.1097/MCO.0000000000000301. [PubMed] [CrossRef] [Google Scholar]
64. Cabrera D., Ruiz A., Cabello-Verrugio C., Brandan E., Estrada L., Pizarro M., Solis N., Torres J., Barrera F., Arrese M. Diet-induced nonalcoholic fatty liver disease is associated with sarcopenia and decreased serum insulin-like growth factor-1. Dig. Dis. Sci. 2016;61:3190–3198. doi: 10.1007/s10620-016-4285-0. [PubMed] [CrossRef] [Google Scholar]
65. Gatineau E., Savary-Auzeloux I., Migné C., Polakof S., Dardevet D., Mosoni L. Chronic intake of sucrose accelerates sarcopenia in older male rats through alterations in insulin sensitivity and muscle protein synthesis. J. Nutr. 2015;145:923–930. doi: 10.3945/jn.114.205583. [PubMed] [CrossRef] [Google Scholar]
66. Stephens F.B., Chee C., Wall B.T., Murton A.J., Shannon C.E., van Loon L.J.C., Tsintzas K. Lipid-induced insulin resistance is associated with an impaired skeletal muscle protein synthetic response to amino acid ingestion in healthy young men. Diabetes. 2015;64:1615–1620. doi: 10.2337/db14-0961. [PubMed] [CrossRef] [Google Scholar]
67. Crescenzo R., Bianco F., Coppola P., Mazzoli A., Cigliano L., Liverini G., Iossa S. The effect of high-fat—High-fructose diet on skeletal muscle mitochondrial energetics in adult rats. Eur. J. Nutr. 2015;54:183–192. doi: 10.1007/s00394-014-0699-7. [PubMed] [CrossRef] [Google Scholar]
68. Riboulet-Chavey A., Pierron A., Durand I., Murdaca J., Giudicelli J., van Obberghen E. Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes. 2006;55:1289–1299. doi: 10.2337/db05-0857. [PubMed] [CrossRef] [Google Scholar]
69. Wang D.D., Sievenpiper J.L., de Souza R.J., Chiavaroli L., Ha V., Cozma A.I., Mirrahimi A., Yu M.E., Carleton A.J., Di Buono M., et al. The effects of fructose intake on serum uric acid vary among controlled dietary trials. J. Nutr. 2012;142:916–923. doi: 10.3945/jn.111.151951. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
70. Cox C.L., Stanhope K.L., Schwarz J.M., Graham J.L., Hatcher B., Griffen S.C., Berglund L., McGahan J.P., Keim N.L., Havel P.J. Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans. Nutr. Metab. (Lond.) 2012;9:68. doi: 10.1186/1743-7075-9-68. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
71. Zhu Y., Hu Y., Huang T., Zhang Y., Li Z., Luo C., Luo Y., Yuan H., Hisatome I., Yamamoto T., et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem. Biophys. Res. Commun. 2014;447:707–714. doi: 10.1016/j.bbrc.2014.04.080. [PubMed] [CrossRef] [Google Scholar]
72. Fabbrini E., Serafini M., Colic Baric I., Hazen S.L., Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2014;63:976–981. doi: 10.2337/db13-1396. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
73. Ou H.-Y., Wu H.-T., Hung H.-C., Yang Y.-C., Wu J.-S., Chang C.-J. Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance. Endocrinology. 2012;153:2974–2984. doi: 10.1210/en.2011-2043. [PubMed] [CrossRef] [Google Scholar]
74. Marchand A., Tomkiewicz C., Magne L., Barouki R., Garlatti M. Endoplasmic reticulum stress induction of insulin-like growth factor-binding protein-1 involves ATF4. J. Biol. Chem. 2006;281:19124–19133. doi: 10.1074/jbc.M602157200. [PubMed] [CrossRef] [Google Scholar]
75. Srinivas P.R., Wagner A.S., Reddy L.V., Deutsch D.D., Leon M.A., Goustin A.S., Grunberger G. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol. Endocrinol. 1993;7:1445–1455. [PubMed] [Google Scholar]
76. Crossey P.A., Jones J.S., Miell J.P. Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes. 2000;49:457–465. doi: 10.2337/diabetes.49.3.457. [PubMed] [CrossRef] [Google Scholar]
77. Jiang S., Yan C., Fang Q., Shao M., Zhang Y., Liu Y., Deng Y.P., Shan B., Liu J.Q., Li H.T., et al. Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J. Biol. Chem. 2014;289:29751–29765. doi: 10.1074/jbc.M114.565960. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
78. Liu J., Xu Y., Hu Y., Wang G. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism. 2015;64:380–390. doi: 10.1016/j.metabol.2014.11.009. [PubMed] [CrossRef] [Google Scholar]
79. Hong S.-H., Ahmadian M., Yu R.T., Atkins A.R., Downes M., Evans R.M. Nuclear receptors and metabolism: From feast to famine. Diabetologia. 2014;57:860–867. doi: 10.1007/s00125-014-3209-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
80. Wolfe B.M., Ahuja S.P., Marliss E.B. Effects of intravenously administered fructose and glucose on splanchnic amino acid and carbohydrate metabolism in hypertriglyceridemic men. J. Clin. Investig. 1975;56:970–977. doi: 10.1172/JCI108177. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
81. Hundal H.S., Darakhshan F., Kristiansen S., Blakemore S.J., Richter E.A. GLUT5 expression and fructose transport in human skeletal muscle. Adv. Exp. Med. Biol. 1998;441:35–45. [PubMed] [Google Scholar]
82. Laughlin M.R. Normal roles for dietary fructose in carbohydrate metabolism. Nutrients. 2014;6:3117–3129. doi: 10.3390/nu6083117. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
83. Leverve X. Rôle du foie dans le métabolisme des nutriments en nutrition artificielle. Nutr. Clin. Métabol. 1999;13:225–231. doi: 10.1016/S0985-0562(99)80050-8. [CrossRef] [Google Scholar]
84. Lazo M., Solga S.F., Horska A., Bonekamp S., Diehl A.M., Brancati F.L., Wagenknecht L.E., Pi-Sunyer F.X., Kahn S.E., Clark J.M., et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33:2156–2163. doi: 10.2337/dc10-0856. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
86. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., Fava J.L., Wing R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129. doi: 10.1002/hep.23276. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
87. Alwahsh S.M., Xu M., Schultze F.C., Wilting J., Mihm S., Raddatz D., Ramadori G. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLoS ONE. 2014;9:e104220. doi: 10.1371/journal.pone.0104220. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
88. Godos J., Federico A., Dallio M., Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: Molecular mechanisms of protection. Int. J. Food Sci. Nutr. 2017;68:18–27. doi: 10.1080/09637486.2016.1214239. [PubMed] [CrossRef] [Google Scholar]
89. Ryan M.C., Itsiopoulos C., Thodis T., Ward G., Trost N., Hofferberth S., O’Dea K., Desmond P.V., Johnson N.A., Wilson A.M. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J. Hepatol. 2013;59:138–143. doi: 10.1016/j.jhep.2013.02.012. [PubMed] [CrossRef] [Google Scholar]
90. Parker H.M., Johnson N.A., Burdon C.A., Cohn J.S., O’Connor H.T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 2012;56:944–951. doi: 10.1016/j.jhep.2011.08.018. [PubMed] [CrossRef] [Google Scholar]
91. Alwahsh S.M., Ramadori G. How does bariatric surgery improve Type II Diabetes? The neglected importance of the liver in clearing glucose and insulin from the portal blood. J. Obes. Weight Loss Ther. 2015;5:280. doi: 10.4172/2165-7904.1000280. [CrossRef] [Google Scholar]
92. Alwahsh S.M., Gebhardt R. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD) Arch. Toxicol. 2016 doi: 10.1007/s00204-016-1892-7. [PubMed] [CrossRef] [Google Scholar]
93. Chen Q., Wang T., Li J., Wang S., Qiu F., Yu H., Zhang Y., Wang T. Effects of natural products on fructose-induced nonalcoholic fatty liver disease (NAFLD) Nutrients. 2017;9:96. doi: 10.3390/nu9020096. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
94. Spruss A., Kanuri G., Stahl C., Bischoff S.C., Bergheim I. Metformin protects against the development of fructose-induced steatosis in mice: Role of the intestinal barrier function. Lab. Investig. 2012;92:1020–1032. doi: 10.1038/labinvest.2012.75. [PubMed] [CrossRef] [Google Scholar]
95. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. doi: 10.1002/hep.25762. [PubMed] [CrossRef] [Google Scholar]
2 thoughts on “အပိုင်း(၇)ဆီးချိုရောဂါ၏လူမသိသေးသောလျို့ဝှက်ချက်များ။”
., Méndez-Lucas A., Shelton J.M., Perales J.C., Browning J.D., Burgess S.C. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J. Lipid Res. 2012;53:1080–1092. doi: 10.1194/jlr.M023382. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
အပိုင်း(၇)ဆီးချိုရောဂါ၏လူမသိသေးသောလျို့ဝှက်ချက်များ (၂)ခါထပ်နေပါသည်။
အပိုင်း(၈)ရှာမတွေ့ပါ။အပိုင်း(၈)ဆက်ဖတ်လိုပါသဖြင့်ပြန်တင်ပေး။
အပိုင်း(၇)ဆီးချိုရောဂါ၏လူမသိသေးသောလျို့ဝှက်ချက်များ (၂)ခါထပ်နေပါသည်။
အပိုင်း(၈)ရှာမတွေ့ပါ။အပိုင်း(၈)ဆက်ဖတ်လိုပါသဖြင့်ပြန်တင်ပေးပါ။